Network officials also said voters should expect more of a Koch focus on grassroots activism throughout the 2020 election cycle.Politicsread more
Stores are extending hours and cities are spending on light shows as China tries to encourage consumers to spend more money at night.China Economyread more
Stocks in Asia Pacific edged up in Friday morning trade as a series of developments overnight on the U.S.-China trade front dampened hopes.Asia Marketsread more
GM's usage of temporary workers, potential closure of plants and health care contributions remain major sticking points, according to people familiar with the talks.Autosread more
Gunfire erupted on the streets of Washington, D.C., on Thursday night and at least several people were shot, local media reported.U.S. Newsread more
In a room full of avowed capitalists, policies that sound to some like socialism are bound not to go over well.Delivering Alpharead more
Trump has criticized Facebook numerous times since becoming president, most recently posting on Twitter that the company's proposed digital currency, libra, will "have little...Technologyread more
Republicans and Democrats have long since separated themselves by ideology, leaving each more uniformly conservative or liberal than ever. And now a new data analysis by the...Politicsread more
Asian cities are on the rise and are dominant in the Fintech space.Financeread more
At least in terms of monetary policy, Pence says should be taking after other regions who keep their benchmark interest rates near zero.Delivering Alpharead more
The Pentagon on Thursday said the recent attack on Saudi Arabian oil facilities were "sophisticated" and represented a "dramatic escalation" in tensions within the region.Defenseread more
Believe it or not, when "Mad Money" first came on the air a decade ago, Cramer had a hard time getting executives to appear on the show.
The very first CEO interview was with Dr. Len Schleifer, who was at the time the CEO of a small development stage biotech company called Regeneron.
At the time the stock traded just above $4, and as of Monday it closed at $426. Cramer gave this stock his blessing for speculation, and the company turned out to be one of the best blessings he has ever given. Its cholesterol drug has been a big hit, and Cramer thinks it could bring the stock even higher.
Could the company foresee that it would be so profitable? Cramer sat down with Dr. Schleifer 10 years later to find out.
"The thing about this business is that it's all based on what you do for patients. This is not the soap business or the detergent business where the marketing clout matters. The bottom line is if you come out with a product that makes a difference for patients you're going to sell the product, patients are going to do better and your investors and shareholders are going to profit as well," Schleifer said.
Read more from Mad Money with Jim Cramer
Cramer: The Fed still knows nothing
Cramer: Relax! Here's how to deal with the decline
Ford CEO: Strong dollar? No problem
The CEO elaborated that when Regeneron first began, it took a big risk with not a lot of support.
"We thought that if we just stuck with the science we could get there. We didn't know how long it would take, and didn't have a lot of people who believed in us," Schleifer added.
Cramer is one of those people who believed in the stock, which has increased more than ten fold since inception. He still considers it to be one one of his top biotech stocks.